OncoTherics’ U.S. clinical translational strategy was advanced this week through discussions with key colleagues at Memorial Sloane Kettering Cancer Centre (New York) and MD Anderson Cancer Center (Houston, Texas). The company has identified a number of key clinicians with experience and expertise in dealing with cancer treatment failure, driven by hypoxic progression.

The company is in collaborative discussions to progress its next generation uHAP, OCT1002, towards clinical trials in the USA.